BioNanoSim

Developing drug delivery technology that deposits polymeric biodegradable nanoparticles into the body.

Health Tech & Life Sciences
Active
Seed Jerusalem, Israel Founded 2015
Last updated 2026-07-20
Total raised
$6.0M
Last: Undisclosed Round 2016-01
Stage
Seed
Founded
2015
Headcount
6
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

BioNanoSim (BNS) is an Israeli startup focused on developing drug delivery technology using proprietary nano-encapsulation to improve the delivery, stability, and bioactivity of drugs. The company, a spin-off from the Hebrew University, reformulates existing drugs and creates new therapeutic products across various verticals including ophthalmology, obesity, oncology, and cannabis. In 2023, BioNanoSim partnered with Greek pharma firm RAFARM to create BNS Ophthalmics (BNSO), a new company dedicated to marketing novel treatments for eye diseases.

Funding history · 1 round · $6.0M total

2016-01
Undisclosed Round $6.0M

Headcount over time

From 12 (2019-11) to 6 (2025-10) · -6 (-50%) · 4 points · source: Finder history + radar grounding
120 2019-11 2025-10

Q&A

What is BioNanoSim's primary focus?
BioNanoSim (BNS) specializes in developing a proprietary technology platform for the nano-encapsulation of drugs to enhance delivery profiles and therapeutic performance.
When was BioNanoSim founded?
BioNanoSim was founded in July 2015.
Where is BioNanoSim headquartered?
BioNanoSim is headquartered in Jerusalem, Jerusalem District, Israel.
How much funding has BioNanoSim raised to date?
BioNanoSim has raised a total of $6,000,000 USD.
When was BioNanoSim's last funding round?
BioNanoSim's last funding round occurred in January 2016, raising $6,000,000 USD.
What is BioNanoSim's current employee count?
BioNanoSim has 1-10 employees.
Who is the founder of BioNanoSim?
Professor Simon Benita is the Founder & Chairman of BioNanoSim.
What therapeutic areas does BioNanoSim's technology address?
BioNanoSim's nano-encapsulation technology has potential applications across oncology, ophthalmology, and metabolic diseases. Additionally, the company is developing topical and ocular cannabis-based products.

Team · 1

Prof. Simon Benita
Founder · Founder, CEO & Chairman

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical Cannabis
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

pharma-companiescancerpharmaceuticalsnanotechnologydrug-deliveryhealthcare-providerscannabistreatmentsbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitebionanosim.com/
LinkedInlinkedin.com/company/77224750

Identifiers & details

Founded2015
Employees (exact)6

Radar intelligence

Patents

EPO2

Publications (Crossref)

Works1

Web history (Wayback)

Domainbionanosim.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515268241
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2015-06-14
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens0
Registry events3 — shares_capital (2), other (1)
Registered addressויסבורג חיים 6 תל אביב - יפו

Recent registry events

DateEvent
2025-09-18העברת מניות
2025-09-11הקצאת מניות
2026-06-04עדכון כתובת ו/או מען דיגיטלי